| Source | us.nlm.vsac#0.11.0:null (v4.0.1) |
| resourceType | ValueSet |
| id | 2.16.840.1.113883.3.666.5.2350 |
| canonical | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350 |
| version | 20160331 |
| status | active |
| publisher | Lantana EH Steward |
| name | ImmunocompromisedTherapiesI9 |
| title | Immunocompromised Therapies I9 |
| date | 2016-03-31T01:00:12-04:00 |
| experimental | false |
| Usages |
|
This value set contains 5 concepts
| Code | System | Display |
| 00.10 | http://hl7.org/fhir/sid/icd-9-cm | Implantation of chemotherapeutic agent |
| 00.15 | http://hl7.org/fhir/sid/icd-9-cm | High-dose infusion interleukin-2 [IL-2] |
| 17.70 | http://hl7.org/fhir/sid/icd-9-cm | Intravenous infusion of clofarabine |
| 99.25 | http://hl7.org/fhir/sid/icd-9-cm | Injection or infusion of cancer chemotherapeutic substance |
| 99.28 | http://hl7.org/fhir/sid/icd-9-cm | Injection or infusion of biological response modifier [BRM] as an antineoplastic agent |
Produced 08 Sep 2023